What is a clinical trial?

Clinical trials are research studies designed to evaluate experimental treatments and procedures. Most breakthroughs in the diagnosis, treatment, and care of patients with cancer exist because of clinical trials.

Clinical trials have specific treatment plans with specific eligibility criteria. Criteria differ from study to study, and are frequently based on age, sex, type/stage of cancer, medical history, and current health status. Participation in a trial requires the ability to travel to the clinical trial center (in this case, the Saint John’s Cancer Institute).

Search for Open Clinical Trials at Saint John’s Cancer Institute.

What is it like to participate in a clinical trial?

Mark Perzley is interviewed by Saint John’s Cancer Institute in Santa Monica, California.

Saint John’s Experts Explain the Importance of Clinical Trials

Doctors, Kim Margolin, Santosh Kesari, Przemyslaw Twardowski, Parvin Peddi, Leland Foshag, and Emma Chacon deep dive into clinical trials and their significance to their patients and others.

Have questions?

For more information about any of our clinical trials, or general questions, please call our main hotline.   See Clinical Trials FAQs for additional information.

The clinical trials listed below represent active and enrolling trials. We implement, initiate, and oversee clinical trials here, at Saint John’s Cancer Institute, as well as other facilities in the Southern California region.

Search using key terms or filter by Centers of Excellence or by Lead Doctor.

Title Center Name Physician

Study of the Bria-IMT Regimen and CPI vs Physicians’ Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

NCT ID : 06072612
Phase : 3
Location : Saint John's Cancer Institute

Breast Surgery and Oncology

Parvin Peddi, M.D.

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

NCT ID : 05483868
Phase : 1
Location : Saint John's Cancer Institute

Urology and Urologic Oncology

Jennifer Linehan, M.D.

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

NCT ID : 05852691
Phase : 2
Location : Saint John's Cancer Institute

Breast Surgery and Oncology

Reva Basho, M.D.

Perioperative Pain Management Strategies in Oncoplastic Breast Surgery

NCT ID : N/A
Phase : N/A
Location : Saint John's Cancer Institute

Breast Surgery and Oncology

Janie Grumley, M.D.

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (Solar-Recur)

NCT ID : 06235151
Phase : 3
Location : Saint John's Cancer Institute

Urology and Urologic Oncology

Przemyslaw Twardowski, M.D.

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (Solar-Recur)

NCT ID : 06235099
Phase : 3
Location : Saint John's Cancer Institute

Urology and Urologic Oncology

Przemyslaw Twardowski, M.D.

A Randomized Controlled Phase 2 Study of the Ketogenic Diet Versus Standard Dietary Guidance for Patients With Newly Diagnosed Glioblastoma in Combination With Standard-of-care Treatment

NCT ID : 05708352
Protocol Number : IIT2022-06-HU-DIET2TREAT
Phase : 2
Location : Santa Monica, CA

Brain Tumors & Neuroscience

Akanksha Sharma, M.D.

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT ID : 05894239
Protocol Number : WO44263
Phase : 3
Location : Burbank, California

Breast Surgery and Oncology

Reva Basho, M.D.

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial

NCT ID : 05554380
Protocol Number : EAY191-S3
Phase : 2
Location : Santa Monica, CA

Multiple Tumors

Reva Basho, M.D.

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

NCT ID : 05554354
Phase : 2
Location : Santa Monica, CA

Breast Surgery and Oncology

Reva Basho, M.D.

Testing the Role of FDG-PET/​CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

NCT ID : 05710328
Protocol Number : EA1211
Phase : 2
Location : Santa Monica, Ca

Breast Surgery and Oncology

Parvin Peddi, M.D.

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT ID : 05608291
Protocol Number : R3767-ONC-2055
Phase : 3
Location : Saint John's Cancer Institute

Melanoma, Skin and Soft Tissue Tumors

Kim Margolin, M.D.

A Beta-only IL-2 Immunotherapy Study (ABILITY-1)

NCT ID : 05086692
Protocol Number : MDNA 11-01
Phase : 1/2
Location : Saint John's Cancer Institute

All Solid Tumors

Przemyslaw Twardowski, M.D.

A Study of ARV-766 Given by Mouth in Men With Metastatic Castration-resistant Prostate Cancer Who Have Progressed on Prior Approved Systemic Therapies

NCT ID : 05067140
Protocol Number : ARV-766mCRPC-101
Phase : 1/2
Location : Saint John's Cancer Institute

Urology and Urologic Oncology

Przemyslaw Twardowski, M.D.

Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

NCT ID : 03972657
Protocol Number : R5678-ONC-1879
Phase : 1/2
Location : Saint John's Cancer Institute

Urology and Urologic Oncology

Przemyslaw Twardowski, M.D.

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

NCT ID : 05812807
Protocol Number : A012103
Phase : 3
Location : Saint John's Cancer Institute

Breast Surgery and Oncology

Parvin Peddi, M.D.

A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors)

NCT ID : 05155332
Protocol Number : 1456-0001
Phase : 1
Location : Saint John's Cancer Institute

All Solid Tumors

Naveed Wagle, M.D.

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION)

NCT ID : 05580562
Protocol Number : ONC201-108
Phase : 3
Location : Saint John's Cancer Institute

Brain Tumors & Neuroscience

Akanksha Sharma, M.D.

Biomarker Low Risk Node Positive Breast Cancer: TAILOR RT.

NCT ID : 03488693
Protocol Number : CCTGMA.39
Phase : 3
Location : Santa Monica, CA

Breast Surgery and Oncology

Janie Grumley, M.D.

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study

NCT ID : 05568472
Protocol Number : SWOG-S2010
Phase : 3
Location : Saint John's Cancer Institute

Breast Surgery and Oncology

Janie Grumley, M.D.

White Button Mushroom Supplement for Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Naïve Patients 

NCT ID : 04519879
Protocol Number : White Button Mushroom
Phase : 2
Location : Santa Monica, CA

Urology and Urologic Oncology

Przemyslaw Twardowski, M.D.

Intermediate-size Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas

NCT ID : 04617002
Protocol Number : ONC028
Phase : N/A
Location : Santa Monica, CA

Brain Tumors & Neuroscience

Akanksha Sharma, M.D.

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma

NCT ID : 05561374
Protocol Number : OKN-007-OL
Phase : 1
Location : Saint John's Cancer Institute

Brain Tumors & Neuroscience

Naveed Wagle, M.D.

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

NCT ID : N/A
Protocol Number : CBI_2019_SLNBprosp_001
Phase : N/A
Location : Santa Monica, CA

Melanoma, Skin and Soft Tissue Tumors

Richard Essner, M.D.